Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology to Present at the Jefferies Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancer
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
11:22pm, Tuesday, 21'st May 2024
Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it o
Cardiff Oncology to Present at Upcoming Investor Conferences in May
04:05pm, Monday, 13'th May 2024
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancer
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
06:00am, Tuesday, 07'th May 2024
Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
01:30am, Friday, 03'rd May 2024
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Execut
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
06:46pm, Thursday, 02'nd May 2024
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
04:05pm, Thursday, 02'nd May 2024
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
04:05pm, Thursday, 25'th Apr 2024
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.
Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?
04:30pm, Tuesday, 09'th Apr 2024
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascula
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Monday, 01'st Apr 2024
Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
04:05pm, Thursday, 21'st Mar 2024
You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
08:56am, Thursday, 21'st Mar 2024
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
09:51am, Thursday, 14'th Mar 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recen
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
09:11am, Thursday, 14'th Mar 2024
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term
